Health Technology · Pharmaceuticals: Major · NSE: PFIZER · data 2026-10-09

PFIZER LIMITED

Health check: Average (6/10 on quality, valuation vs sector, growth and momentum).

Open full analysis — chart, results, balance sheet, red flags →

Key figures

Price

₹3,808.2

Market cap

₹17,153 cr

P/E

23.7

P/B

—

ROE

17.2%

ROCE

20.0%

Debt / equity

0.02

Dividend yield

2.00%

1-year return

-26.3%

52-week high

₹5,578.5

52-week low

₹3,731

Operating margin

34.4%

Growth

Revenue (last 12 months)	₹2,570 cr
Net profit (last 12 months)	₹735 cr
Sales growth, 3 years (yearly)	1.3%
Profit growth, 3 years (yearly)	5.0%

Chart patterns

Double top — breakdown (key level ₹4,360.1)

Similar companies

OneSource Specialty Pharma Limited (ONESOURCE) · Cohance Lifesciences Ltd (COHANCE) · Alivus Life Sciences Ltd (ALIVUS) · Eris Lifesciences Ltd (ERIS) · Alembic Pharmaceuticals Limited (APLLTD)

The full analysis has the price chart, every quarterly result with YoY/QoQ growth, the balance sheet and cash flow with an accounting red-flag check, shareholding quarter by quarter with big investors, news, filings and bulk/block deals.

Open PFIZER in NSE Scanner →